-
公开(公告)号:US20240168447A1
公开(公告)日:2024-05-23
申请号:US18280673
申请日:2021-04-02
Applicant: Mitsubishi Electric Corporation , OSAKA UNIVERSITY
Inventor: Kohei FUJITA , Toshimitsu USHIO
IPC: G05B19/042 , G05B19/05 , G05B19/408
CPC classification number: G05B19/0426 , G05B19/056 , G05B19/408
Abstract: Operating efficiency of a target to be controlled is enhanced, and a degree of freedom in converting a language of a program is enhanced. A program generation apparatus includes: a design information conversion unit that converts design information, which includes a plurality of states of a device, relationships between signals and the states of the device, and time required for changes of the states of the device, into a model, which includes a state set, an input set, a transition function, and time required for transitions; a control law derivation unit that derives a control law, based on a requirements specification including a specification related to the time required for the transitions and the model, so as to satisfy the requirements specification; and a program generation unit that generates a program, based on the control law.
-
公开(公告)号:US20240158790A1
公开(公告)日:2024-05-16
申请号:US18392869
申请日:2023-12-21
Inventor: Takanori Yokota , Kazutaka Nishina , Satoshi Obika , Hidehiro Mizusawa
IPC: C12N15/113 , C12N15/11
CPC classification number: C12N15/113 , C12N15/111 , C12N2310/11 , C12N2310/15 , C12N2310/3181 , C12N2310/3231 , C12N2310/341 , C12N2310/3513 , C12N2310/3515 , C12N2310/53 , C12N2320/52
Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.
-
53.
公开(公告)号:US20240157164A1
公开(公告)日:2024-05-16
申请号:US18284467
申请日:2022-03-25
Applicant: OSAKA UNIVERSITY
Inventor: Masakazu YAGI , Yoshiki SAWA , Hirotada MASUDA , Kotaro YOSHIDA , Fumito MINAKAMI , Eri KANEDA
Abstract: In order to provide a technical means that offers excellent convenience, usability, and safety for stellate ganglion block that can effectively suppress sympathetic overexcitation, this stellate ganglion magnetic stimulation device comprises: a head unit having a magnet for generating magnetism; and a neck unit that is removably worn around a wearer's neck and that presses the head unit against epidermis corresponding to the stellate ganglion so that stimulation by the magnetism acts on the stellate ganglion.
-
公开(公告)号:US20240150691A1
公开(公告)日:2024-05-09
申请号:US18280659
申请日:2022-03-09
Applicant: Kyoto University , OSAKA UNIVERSITY
Inventor: Kazuo TAKAYAMA , Yusuke TORISAWA , Kenji OSAFUNE , Maki KOTAKA , Sayaka DEGUCHI , Hiroyuki MIZUGUCHI
Abstract: There is provided a bile duct chip that is a bile duct chip (200) including a membrane (210) through which substances are movable from one surface to the other surface, a first substrate (221) having a recessed part that forms a first flow path (220), and a second substrate (231) having a recessed part that forms a second flow path (230), in which the first substrate (221), the membrane (210), the second substrate (231) are stacked in this order, the recessed part of the first substrate (221) has an opening portion facing the one surface of the membrane (210), the recessed part of the second substrate has an opening portion facing the other surface of the membrane (210), the one surface of the membrane (210) forms a part of the first flow path (220), the other surface of the membrane (210) forms a part of the second flow path (230), the first flow path (220) and the second flow path (230) communicate with each other through the membrane (210), and bile duct epithelial cells (222) are disposed on a surface of an inner wall of the first flow path (220) to form a tube.
-
公开(公告)号:US11975040B2
公开(公告)日:2024-05-07
申请号:US16309957
申请日:2017-06-16
Applicant: The University of Tokyo , Osaka University
Inventor: Hiroaki Suga , Nasir Kato Bashiruddin , Junichi Takagi , Yukiko Matsunaga
IPC: A61K38/02 , A61K9/00 , A61K38/04 , A61P9/00 , A61P19/00 , A61P19/08 , A61P25/28 , A61P35/00 , A61P43/00 , C07K7/50
CPC classification number: A61K38/02 , A61K9/0019 , A61K9/0053 , A61K38/04 , A61P19/00 , A61P19/08 , A61P25/28 , A61P35/00 , A61P43/00 , C07K7/50
Abstract: The present invention provides a Plexin-binding regulating agent containing a cyclic peptide having an Arg-Trp-Thr structure or a Leu-Ser-Trp structure or a pharmaceutically acceptable salt of the cyclic peptide.
-
56.
公开(公告)号:US11969459B2
公开(公告)日:2024-04-30
申请号:US16477878
申请日:2018-01-26
Applicant: StemRIM Inc. , OSAKA UNIVERSITY
Inventor: Katsuto Tamai , Yoshiki Sawa , Shigeru Miyagawa , Takashi Kido , Takasumi Goto , Takehiko Yamazaki
Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and/or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.
-
公开(公告)号:US20240124898A1
公开(公告)日:2024-04-18
申请号:US18467297
申请日:2023-09-14
Applicant: OSAKA UNIVERSITY
Inventor: Tomoji MASHIMO , Junji TAKEDA , Hiroyuki MORISAKA , Kazuto YOSHIMI
CPC classification number: C12N15/907 , A61K48/00 , C12N5/14 , C12N5/16 , C12N9/22 , C12N15/85 , C12N15/8509 , C12N2310/20 , C12N2800/22 , C12N2800/80
Abstract: A CRISPR-Cas3 system was successfully established in a eukaryotic cell.
-
58.
公开(公告)号:US20240122533A1
公开(公告)日:2024-04-18
申请号:US18546448
申请日:2021-11-15
Applicant: OSAKA UNIVERSITY , HEARTLAB, INC.
Inventor: Shigeru MIYAGAWA , Yoshiki SAWA , Hidetsugu ASANOI , Sunao IKEGAWA
CPC classification number: A61B5/4842 , A61B5/0816 , A61B5/6892 , A61B2562/0247
Abstract: The present invention relates to an evaluation device 4 for evaluating the severity of pneumonia in a target patient, comprising: an acquisition unit 42 for acquiring a respiratory waveform of the target patient; a calculation unit 43 for calculating a value of an index indicating instability of a respiratory cycle or a respiratory frequency from the respiratory waveform; and an evaluation unit 44 for evaluating the severity based on the calculated value.
-
公开(公告)号:US20240110830A1
公开(公告)日:2024-04-04
申请号:US18275245
申请日:2021-12-20
Applicant: Osaka University
Inventor: Katsumasa FUJITA , Kazuki BANDO
CPC classification number: G01J3/0216 , G01J3/0208 , G01J3/0224 , G01J3/04 , G01J3/2823 , G01J2003/045
Abstract: A spectrometry apparatus (1) according to an embodiment includes a detection object lens that signal light from a sample S enters, a slit (41) through which the signal light passes, a wavelength dispersive element that disperses the signal light having passed the slit (41) in accordance with a wavelength, an optical detector (50) that detects the signal light that has been subjected to wavelength dispersion in the wavelength dispersive element, scanning means for scanning a detection region of the optical detector (50) in the sample, a processing unit (51) that generates a spectral image, based on a detection signal of the optical detector (50), and an illumination optical system (10) that illuminates the sample from a side of the detection object lens.
-
公开(公告)号:US20240091341A1
公开(公告)日:2024-03-21
申请号:US18032545
申请日:2021-10-18
Inventor: Yasuo YOSHIOKA
IPC: A61K39/215 , A61P37/04 , C07K14/005 , C12N9/24
CPC classification number: A61K39/215 , A61P37/04 , C07K14/005 , C12N9/2402 , C12Y302/01018 , A61K2039/543
Abstract: The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. The present invention contains the fusion protein, which includes hemagglutinin and a receptor binding domain of SARS-CoV-2, and a vaccine containing the fusion protein.
-
-
-
-
-
-
-
-
-